Phaseline

Companies › Zhejiang ACEA Pharmaceutical

Zhejiang ACEA Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STI-6129
anti-CD38 antibody-drug conjugate with duostatin tubulin inhibitor
CD38Phase 1Relapsed or Refractory Multiple MyelomaDec 2026
STI-8591–Phase 1AML, Adult–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05947344STI-8591Phase 1AML, AdultOncologyDec 2025
NCT05565807STI-6129Phase 1Relapsed or Refractory Multiple MyelomaOncologyDec 2026

Targets

CD38 (1)

Companies with the same targets

Takeda Johnson & Johnson (Janssen) Biogen CASI pharmaceuticals Sanofi Celltrion GSK Sinocelltech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.